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ABSTRACT  74 
Background: Phase 2 psoriasis studies with the Fc-free, PEGylated, anti-tumor necrosis factor biologic 75 
certolizumab pegol demonstrated meaningful clinical activity.  76 
Objective: Assess safety and efficacy of certolizumab in adults with moderate-to-severe chronic plaque 77 
psoriasis.  78 
Methods: Patients were randomized 3:3:1:3 to certolizumab 400 mg, 200 mg, or placebo every 2 weeks 79 
for 16 weeks or etanercept 50 mg twice-weekly for 12 weeks. Certolizumab-treated patients achieving 80 
≥75% reduction in psoriasis area and severity index at Week 16 were re-randomized to certolizumab or 81 
placebo for 32 weeks. The primary endpoint was responder rate (≥75% reduction in psoriasis area and 82 
severity index) versus placebo (primary analysis) and etanercept (secondary analysis) at Week 12; 83 
secondary endpoints included responder rates on various measures versus placebo at Weeks 12, 16, and 84 
48. Safety was assessed by treatment-emergent adverse events.  85 
Results: All endpoints were significantly greater for certolizumab versus placebo with the greatest 86 
response seen with 400 mg. Certolizumab 400 mg was superior to and 200 mg was noninferior to 87 
etanercept. Adverse events were consistent with the anti-tumor necrosis factor class. 88 
Limitations: Single-blind etanercept. 89 
Conclusion: Both certolizumab regimens improved psoriasis symptoms with greater response at the 90 
higher dose. No new safety signals were observed.   91 
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CAPSULE SUMMARY 92 
• Certolizumab pegol is an Fc-free, PEGylated anti-tumor necrosis factor biologic.  93 
• In this phase 3 study, both certolizumab doses improved psoriasis symptoms at Week 12 that was 94 
maintained, following re-randomization, through Week 48 with a safety profile consistent with its 95 
class. 96 
• The higher dose of certolizumab may provide superior efficacy.  97 
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INTRODUCTION 98 
Plaque psoriasis is a chronic, immune-mediated, inflammatory disease that affects ~3% of the adult US 99 
population1,2 and ~2-6% of adults in Europe.3 Therapy for psoriasis varies by disease severity, with more 100 
severe disease treated with phototherapy, cyclosporine, methotrexate, apremilast, and/or biologic agents. 101 
Phase 3 clinical trials have demonstrated efficacy of biologic agents, however, nearly one-third of patients 102 
will discontinue treatment with their first biologic within 3 years due to loss of efficacy,4 necessitating 103 
additional treatment options.5,6 104 
Certolizumab pegol (CZP) is the only Fc-free, PEGylated, anti-tumor necrosis factor (TNF) biologic. 105 
Because it lacks an IgG Fc region CZP does not bind the neonatal Fc receptor for IgG (FcRn) and is 106 
consequently not expected to undergo FcRn-mediated transfer across the placenta,7 showing minimal 107 
placental transfer of CZP from mothers to infants.8 PEGylation increases the half-life of certolizumab 108 
pegol to 14 days.9 CZP is approved for the treatment of adults with rheumatoid arthritis, psoriatic arthritis, 109 
Crohn’s disease (US), ankylosing spondylitis and non-radiographic axial spondyloarthritis (EU). CZP is 110 
currently under investigation for the treatment of moderate-to-severe plaque psoriasis, with promising 111 
results in two phase 2 studies.10 In this phase 3 trial (CIMPACT; NCT02346240), the efficacy of CZP 112 
compared with placebo and etanercept (ETN) and the safety of CZP were assessed in adults with 113 
moderate-to-severe chronic plaque psoriasis.  114 
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METHODS 115 
Study Design 116 
CIMPACT is an ongoing phase 3, multinational (conducted at outpatient clinic sites in North America 117 
and Europe), randomized, double-blind, parallel-group, placebo-controlled and single-blind 118 
active-controlled trial beginning February 11, 2015 (Figure 1). The data cut-off for this Week 48 analysis 119 
was December 5, 2016. During the Initial Period, patients were randomized 3:3:1:3 (stratified by site) to 120 
CZP 400 mg every 2 weeks (Q2W), CZP 200 mg Q2W (after 400 mg loading dose at Weeks 0, 2, and 4), 121 
or placebo Q2W for 16 weeks or ETN 50 mg twice-weekly for 12 weeks (the CZP loading dose and ETN 122 
starting dose are consistent with the drugs’ approved labeling). Double-blinded CZP and placebo 123 
treatments were administered subcutaneously at the study site by study personnel not involved in any 124 
other study procedures; ETN treatment was administered subcutaneously on-site by unblinded study staff 125 
or self-administered off-site by the patient after sufficient training. To maintain the single-blind for ETN, 126 
efficacy assessments were performed by a designated blinded assessor not involved in any other study 127 
procedures during blinded study periods. Study drug kits were distributed based on the subject’s 128 
interactive voice/web response system-assigned randomization number; the randomization schedule was 129 
produced by an independent biostatistician. 130 
At Week 16, patients achieving ≥75% reduction in the psoriasis area and severity index (PASI 75) were 131 
re-randomized (2:2:1 for each) from CZP 400 mg Q2W to CZP 400 mg Q2W, CZP 200 mg Q2W, or 132 
placebo and from CZP 200 mg Q2W to CZP 400 mg Q4W, CZP 200 mg Q2W, or placebo for the 133 
32-week Maintenance Period. Placebo-treated PASI 75 responders continued placebo for the Maintenance 134 
Period, and ETN-treated PASI 75 responders, following a 4-week washout, were re-randomized (2:1) to 135 
CZP 200 mg Q2W (after 400 mg loading dose at Weeks 16, 18, and 20) or placebo. PASI 75 136 
nonresponders at Week 16 entered an Escape Arm and received treatment with CZP 400 mg Q2W. 137 
Patients who were re-randomized and were PASI 50 nonresponders (<50% reduction in PASI) at any visit 138 
during the Maintenance Period and patients who completed the double-blind Maintenance Period entered 139 
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the open-label safety extension, which is ongoing at the time of this publication, and received CZP 400 140 
mg Q2W. Outcomes at Weeks 12, 16, and 48 are presented here. 141 
The protocol was amended during the study to add PASI 90 as a secondary endpoint. This study was 142 
approved by local institutional review boards (IRBs) or independent ethics committees (non-US sites) and 143 
carried out according to the Declaration of Helsinki.11 Written informed consent was obtained from all 144 
patients, and the protocol received IRB approval (Quorum Review File #30064; December 12, 2014). 145 
This study is registered at ClinicalTrials.gov (NCT02346240) and EudraCT (2014-003492-36).  146 
Study Subjects 147 
Eligible patients were adults with moderate-to-severe plaque psoriasis for ≥6 months with Baseline 148 
PASI ≥12, body surface area (BSA) ≥10%, physician’s global assessment (PGA) ≥3 on a 5-point scale, 149 
and were candidates for systemic psoriasis therapy, phototherapy, and/or photochemotherapy. 150 
Patients were excluded if they had a history of treatment with CZP, ETN, or >2 biologic agents; had 151 
history of primary failure to any biologic (ie, no response within the first 12 weeks of treatment) or 152 
secondary failure to >1 biologic (ie, patient initially responded and then stopped treatment due to loss of 153 
response after Week 12); had erythrodermic, guttate, or generalized pustular psoriasis; had a history of 154 
chronic or recurrent infections, including active or latent (assessed using an interferon-gamma release 155 
assay) tuberculosis, or were at high risk for infection; had a history of lymphoproliferative disorder, 156 
including lymphoma; had a history of malignancy or demyelinating disease of the central nervous system; 157 
had congestive heart failure; were breastfeeding, pregnant, planned to become pregnant, or had a partner 158 
who planned to become pregnant during the study or within 3-5 months following the last dose of study 159 
drug.  160 
Efficacy and Safety Assessments 161 
The primary efficacy endpoint was PASI 75 responder rate for both CZP doses versus placebo at 162 
Week 12. Secondary efficacy endpoints were PASI 75 responder rate versus placebo at Week 16; 163 
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PGA 0/1 responder rate ("clear"/"almost clear" with ≥2-point improvement from Baseline) versus placebo 164 
at Weeks 12 and 16; PASI 90 (≥90% reduction in PASI) responder rate versus placebo at Weeks 12 and 165 
16; PASI 75 responder rate versus ETN at Week 12; and PASI 75 responder rates at Week 48 for patients 166 
achieving PASI 75 at Week 16. Safety was assessed by treatment-emergent adverse events (TEAEs).  167 
Statistical Analysis 168 
Based on previous phase 2 results,10 Week 12 PASI 75 responder rates were assumed to be 80%, 75%, 169 
5%, and 57% for CZP 400 mg, CZP 200 mg, placebo, and ETN,12 respectively. Using these values and a 170 
3:3:1:3 randomization ratio, an overall sample size of 540 provided >90% power to detect a significant 171 
difference between CZP 200 mg and ETN for Week 12 PASI 75 responder rate with a 2-sided alpha-level 172 
of 0.05. The power for the primary endpoint evaluation was >99%. 173 
Efficacy results are reported for patients in randomized and re-randomized treatment groups. Safety 174 
results are reported for all patients, including those in the Escape Arm. Analyses were based on the 175 
Randomized Set (all randomized subjects), Maintenance Set (all patients who completed Week 16 and 176 
had ≥1 efficacy assessment during the Maintenance Period), and Safety Set (all patients who received ≥1 177 
dose of study medication). PASI 75, PGA 0/1, and PASI 90 responder rates were analyzed using a 178 
logistic regression model with fixed effects for treatment, region, and prior biologic exposure (yes/no). 179 
Imputation of missing data was performed using the Markov chain Monte Carlo (MCMC) method for 180 
multiple imputation during the Initial Period and nonresponder imputation during the Maintenance 181 
Period. In a post-hoc analysis, Week 48 PASI 75 responder rates were compared between CZP doses 182 
based on Fisher’s exact test. 183 
The details of the fixed-sequence testing procedure used to account for multiplicity can be found in the 184 
Supplement.   185 
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RESULTS  186 
Patient Disposition, Demographics, and Baseline Characteristics 187 
559 patients were randomized. Completion rates were similar among treatment groups; >90% of 188 
randomized patients completed Week 16 and >90% of Week 16 PASI 75 responders who entered the 189 
Maintenance Phase completed Week 48 (Figure 2). The CZP and ETN treatment groups were well 190 
balanced with respect to Baseline disease characteristics (Table 1). The placebo group had slightly lower 191 
disease activity (BSA, PASI) and less prior biologic use, but also fewer patients compared with other 192 
treatment groups (Table 1).  193 
Efficacy to Week 16 194 
By Week 12, PASI 75 responder rate was significantly greater for CZP-treated patients versus 195 
placebo-treated patients (Table 2). Differences versus placebo occurred as early as Week 4 and increased 196 
through Week 16 (Figure 3). At Week 12, CZP 400 mg was superior and CZP 200 mg was noninferior to 197 
ETN for PASI 75 responder rate (Table 2 and Figure 3). Similar trends occurred for PGA 0/1 and 198 
PASI 90 responder rates for both doses of CZP versus placebo (Figure 4 and Figure 5).  199 
Efficacy from Week 16 to Week 48 200 
Through Week 48, PASI 75 responder rates were greater for patients re-randomized from CZP to either 201 
the same or different dose of CZP compared with those re-randomized to placebo (Figure 6); greater 202 
responses were observed for patients continuing on CZP 400 mg Q2W. In a post hoc analysis, the 203 
Week 48 PASI 75 responder rate was higher for patients re-randomized from CZP 400 mg Q2W to 204 
CZP 400 mg Q2W (98.0%) compared with patients re-randomized to CZP 200 mg Q2W (80.0%) 205 
(p<0.05; Fisher’s exact test); response maintenance was similar for patients re-randomized from 206 
CZP 200 mg Q2W to 400 mg Q4W or 200 mg Q2W. 207 
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Similar trends occurred for Week 48 PGA 0/1 and PASI 90 responder rates (Figures S1 and S2); 208 
however, since subjects were re-randomized based on PASI 75 response rather than PGA 0/1 or PASI 90 209 
response, the proportion of PGA 0/1 or PASI 90 responders varied at re-randomization across the groups. 210 
For Week 16 PASI 75 responders treated with ETN in the Initial Period, Week 48 PASI 75, PGA 0/1, and 211 
PASI 90 responder rates were 8.3%, 4.2%, and 4.2% for patients who re-randomized to placebo in the 212 
Maintenance Period (N=24); and 82.0%, 72.0%, and 78.0% for patients who re-randomized to 213 
CZP 200 mg Q2W in the Maintenance Period (N=50) (data not graphed). Only 2 placebo-treated patients 214 
achieved PASI 75 at Week 16, and continued to receive placebo during the Maintenance Period. 215 
Safety Assessments 216 
By Week 12, TEAEs were reported for similar proportions of patients across treatment groups, with the 217 
greatest proportion reported for patients receiving placebo (Table 3). The most frequently reported 218 
TEAEs (≥5% in any CZP group) were nasopharyngitis and upper respiratory tract infection. Similar 219 
trends were observed for the overall summary of TEAEs to Week 16 (not shown). 220 
From Baseline to Week 48, the incidence rates per 100 patient-years of TEAEs were 201.3 for those 221 
treated with CZP 400 mg Q2W and 214.0 for those treated with 200 mg Q2W or 400 mg Q4W (Table 222 
S1). One patient in the Escape Arm, after 22 weeks of CZP 400 mg Q2W (combined Initial and 223 
Maintenance Periods), had an incidental diagnosis of primary progressive multiple sclerosis. The patient 224 
reported a 2-year history of gait disturbance and recurrent falls predating entry into the clinical study 225 
(none during study) and was referred to a neurologist due to low back pain. The neurologist diagnosed 226 
primary progressive MS after MRI revealed lesions consistent with MS, and the event was considered 227 
unrelated to treatment by the Investigator. A list of serious TEAEs reported through Week 48 can be 228 
found in Table S2.   229 
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DISCUSSION  230 
The efficacy and safety of CZP, an Fc-free, PEGylated anti-TNF biologic, in adult patients with 231 
moderate-to-severe chronic plaque psoriasis have been previously studied in phase 2 trials.10 In this 232 
phase 3 trial of adult patients with moderate-to-severe chronic plaque psoriasis, treatment with CZP 400 233 
mg or 200 mg resulted in statistically significant and clinically meaningful improvements in signs and 234 
symptoms of psoriasis at Weeks 12 and 16 versus placebo, with clinically meaningful differences in PASI 235 
75 responses observed as early as Week 4. At Week 12, CZP 400 mg was superior and CZP 200 mg was 236 
noninferior to ETN for PASI 75 responder rate. 237 
During the Maintenance Period, efficacy and safety data were collected to assess the durability of 238 
treatment effects beyond the Initial Period; re-randomization also allowed for assessment of alternative 239 
dosing regimens. Considering the high number of patients unsatisfied with their current psoriasis 240 
treatment,13 the favorable Q2W dosing frequency offers advantages over etanercept which requires twice 241 
weekly dosing.14,15 Notably, responder rates for patients receiving CZP 400 mg Q4W were similar versus 242 
patients receiving CZP 200 mg Q2W (ie, same cumulative monthly dose). While both dosing regimens 243 
were efficacious, higher response rates derived from CZP 400 mg Q2W dosing. However, the 244 
CZP 200 mg Q2W regimen may offer prescribing flexibility to physicians based on individual patient 245 
considerations.   246 
An important secondary study objective included assessing the optimal maintenance dose of CZP. 247 
CZP-treated patients who were PASI 75 responders at Week 16 continued to respond through Week 48, 248 
with the greatest response achieved in patients receiving CZP 400 mg Q2W in both the Initial and 249 
Maintenance Periods. PGA 0/1 and PASI 90 responder rates continued to increase for patients 250 
randomized to CZP 400 mg Q2W in both study periods. The maintenance of CZP response appears to be 251 
greater than that reported in other short- and long-term clinical trials of biologic agents in psoriasis, 252 
particularly for patients receiving 48 weeks of CZP 400 mg Q2W.16,17 Additionally, some PASI 75 253 
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responders re-randomized from CZP to placebo demonstrated a sustained response to treatment, 254 
suggesting the duration of CZP effect may extend well beyond withdrawal of treatment for some patients.  255 
Adverse events reported in this study were consistent with the safety profile of the anti-TNF class in 256 
patients with moderate-to-severe chronic plaque psoriasis, and with the profile previously reported for 257 
CZP treatment in other indications.10,16,18 Additionally, CZP- and ETN-treated groups had comparable 258 
safety profiles through Week 12, but fewer CZP-treated patients discontinued due to adverse events 259 
compared with ETN-treated patients. No new safety signals were observed with either CZP dose over 48 260 
weeks of treatment, and incidence rates of TEAEs did not increase with longer-term CZP therapy. Adding 261 
to the total phase 3 exposure through Week 48 of 727 patient-years, two additional phase 3 trials 262 
(CIMPASI-1 and CIMPASI-2) also evaluated CZP 200 mg Q2W and 400 mg Q2W treatment, in adult 263 
patients with moderate-to-severe chronic plaque psoriasis. In those trials, the rates of TEAEs through 264 
Week 48 were comparable between both CZP doses and in line with other anti-TNF agents.19,20,21  265 
As with any clinical study, patients in good general health were selected, perhaps leading to better 266 
efficacy outcomes and improved safety than what might be expected in clinical practice.22 ETN treatment 267 
was limited to the initial 12-week period and single-blind (versus double-blind with CZP and placebo), 268 
but this was not expected to affect treatment comparisons; additionally, considerable efforts were taken to 269 
minimize risk of bias (ie, designated blinded efficacy assessors). Since CZP is approved for several 270 
indications and has clinical and post-marketing data, the total number of patients treated with CZP in this 271 
study was lower than other phase 3 psoriasis trials, especially for re-randomized patients within the 272 
Maintenance Set. Despite these limitations, the data are applicable to the general psoriasis population, 273 
given that the patient demographics were typical of other phase 3 psoriasis programs, efficacy was similar 274 
to that reported in previous phase 2 studies of CZP in psoriasis, and safety issues were consistent with 275 
real-world experience in patients receiving CZP for other conditions. 276 
Overall, treatment with either dose of CZP was associated with significant, clinically meaningful and 277 
sustained improvements in signs and symptoms of moderate-to-severe chronic plaque psoriasis. 278 
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Generally, greater improvements in efficacy outcome measures were recorded at the higher dose. No new 279 
safety signals occurred at either dose over 48 weeks of treatment. These results support that CZP, a 280 
unique anti-TNF biologic, affords a novel treatment option for psoriasis patients.   281 
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Alliance, Beiersdorf UK Ltd, Biotest, Celgene, Dermal, Eli Lilly, Galderma, Genus Pharma, GlobeMicro, 304 
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RR: Employee of UCB Pharma. MA: Consulting honoraria and/or speaker fees for clinical trials 307 
sponsored by companies that manufacture drugs used for the treatment of psoriasis including: AbbVie, 308 
Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly and Company, GSK, 309 
Hexal, Janssen-Cilag, LEO Pharma, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz, UCB 310 
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ABBREVIATIONS AND ACRONYMS 312 
BMI, body mass index 313 
BSA, body surface area 314 
BW, twice weekly 315 
CI, confidence interval 316 
CZP, certolizumab pegol 317 
DLQI, Dermatology Life Quality Index 318 
ETN, etanercept 319 
LD, loading dose 320 
IL, interleukin 321 
OR, odds ratio 322 
PASI 50, ≥50% reduction from Baseline in psoriasis area and severity index 323 
PASI 75, ≥75% reduction from Baseline in psoriasis area and severity index 324 
PASI 90, ≥90% reduction from Baseline in psoriasis area and severity index 325 
PGA, physician’s global assessment 326 
PGA 0/1, ‘clear’ or ‘almost clear’ with ≥2‐category improvement from Baseline in physician’s global 327 
assessment 328 
Q2W, every 2 weeks 329 
Q4W, every 4 weeks 330 
TEAE, treatment-emergent adverse event 331 
TNF, tumor necrosis factor 332 
w/d, withdrawn  333 
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FIGURE LEGENDS 400 
Figure 1. Study Design 401 
BW, twice weekly; CZP, certolizumab pegol; ETN, etanercept; LD, loading dose of CZP 400 mg at 402 
Weeks 0, 2, and 4 or Weeks 16, 18, and 20; PASI 50, ≥50% reduction from Baseline in psoriasis area and 403 
severity index; PASI 75, ≥75% reduction from Baseline in psoriasis area and severity index; Q2W, every 404 
2 weeks; Q4W, every 4 weeks 405 
 406 
Figure 2. Patient Disposition 407 
aPatients received a loading dose of 400 mg at Weeks 0, 2, and 4 408 
bPASI 75 nonresponders at Week 16 entered the Escape Arm for treatment with CZP 400 mg Q2W 409 
cETN-treated PASI 75 responders re-randomized to CZP 200 mg Q2W received an initial loading dose of 410 
400 mg at Weeks 16, 18, and 20 411 
dRepresents the CZP 400 mg Q4W treatment group 412 
eTwo patients completed Week 16 but did not enter the aintenance Period (1 loss to follow-up; 1 413 
consent withdrawn) 414 
CZP, certolizumab pegol; ETN, etanercept; PASI 75, ≥75% reduction from Baseline in psoriasis area and 415 
severity index; Q2W, every 2 weeks; Q4W, every 4 weeks, w/d, withdrawn 416 
 417 
Figure 3. PASI 75 Responder Ratea by Visit to Week 12 (Primary Endpoint) and Week 16 418 
(Randomized Set) 419 
*p<0.05 versus placebo, **p<0.0001 versus placebo (controlled for multiplicity at Weeks 12 and 16); 420 
†noninferior versus ETN (95% CI: [-2.9, 18.9])); ††superior versus ETN (p=0.0152) 421 
aBased on logistic regression model 422 
bCZP 200 mg Q2W patients received loading dose of CZP 400 mg at Weeks 0, 2, and 4 423 
CZP, certolizumab pegol; ETN, etanercept; PASI 75, ≥75% reduction from Baseline in psoriasis area and 424 
severity index; Q2W, every 2 weeks 425 
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Figure 4. PGA 0/1 Responder Ratea by Visit to Week 12 and Week 16 (Randomized Set) 426 
*p<0.05 versus placebo, **p<0.0001 versus placebo (controlled for multiplicity at Weeks 12 and 16); 427 
inferential statistical comparisons of CZP and ETN were not performed 428 
aBased on logistic regression model 429 
bCZP 200 mg Q2W patients received loading dose of CZP 400 mg at Weeks 0, 2, and 4 430 
CZP, certolizumab pegol; ETN, etanercept; PGA 0/1, ‘clear’ or ‘almost clear’ with ≥2‐category 431 
improvement from Baseline in physician’s global assessment; Q2W, every 2 weeks 432 
 433 
Figure 5. PASI 90 Responder Ratea by Visit to Week 12 and Week 16 (Randomized Set) 434 
*p<0.05 versus placebo, **p<0.0001 versus placebo (controlled for multiplicity at Weeks 12 and 16); 435 
inferential statistical comparisons of CZP and ETN were not performed 436 
aBased on logistic regression model 437 
bCZP 200 mg Q2W patients received loading dose of CZP 400 mg at Weeks 0, 2, and 4 438 
CZP, certolizumab pegol; ETN, etanercept; PASI 90, ≥90% reduction from Baseline in psoriasis area and 439 
severity index; Q2W, every 2 weeks 440 
 441 
Figure 6. PASI 75 Responder Ratea by Visit From Week 16 to Week 48 (Maintenance Set) 442 
aBased on nonresponder imputation 443 
CZP, certolizumab pegol; PASI 75, ≥75% reduction from Baseline in psoriasis area and severity index; 444 
Q2W, every 2 weeks; Q4W, every 4 weeks 445 
 446 
  447 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
21 
 
TABLES 448 
Table 1. Patient Demographics and Baseline Disease Characteristics (Randomized Set) 449 
  Placebo 
(N=57) 
ETN 
(N=170) 
CZP 
200 mg Q2W 
(N=165) 
CZP 
400 mg Q2W 
(N=167) 
Demographics     
Age (years), mean ± SD 46.5 ± 12.5 44.6 ± 14.1 46.7 ± 13.5 45.4 ± 12.4 
Male, n (%) 34 (59.6) 127 (74.7) 113 (68.5) 107 (64.1) 
White, n (%) 57 (100)  163 (95.9) 158 (95.8) 162 (97.0) 
Geographic Region, n (%) 
North America 
Central/Eastern Europe 
Western Europe 
 
10 (17.5) 
36 (63.2) 
11 (19.3) 
 
  29 (17.1) 
111 (65.3) 
  30 (17.6) 
 
  26 (15.8) 
107 (64.8) 
  32 (19.4) 
 
  27 (16.2) 
109 (65.3) 
  31 (18.6) 
Weight (kg), mean ± SD 93.7 ± 29.7 88.6 ± 20.7 89.7 ± 20.6 86.3 ± 20.0 
BMI (kg/m2), mean ± SD 31.2 ± 8.5   29.5 ± 6.3   29.8 ± 6.1   28.9 ± 5.9   
Baseline Disease Characteristics     
Duration of psoriasis at screening 
(years), mean ± SD 
18.9 ± 12.9 17.4 ± 12.0 19.5 ± 13.2 17.8 ± 11.5 
Concurrent psoriatic arthritis,a n (%) 12 (21.1)   27 (15.9)   27 (16.4)   24 (14.4) 
PASI, mean ± SD 19.1 ± 7.1   21.0 ± 8.2   21.4 ± 8.8   20.8 ± 7.7   
DLQI, mean ± SD 13.2 ± 7.6   14.1 ± 7.4   12.8 ± 7.0   15.3 ± 7.3   
BSA (%), mean ± SD 24.3 ± 13.8 27.5 ± 15.5 28.1 ± 16.7 27.6 ± 15.3 
PGA score, n (%) 
3: moderate 
4: severe 
 
40 (70.2) 
17 (29.8) 
 
115 (67.6) 
  55 (32.4) 
 
114 (69.1) 
  51 (30.9) 
 
113 (67.7) 
  54 (32.3) 
Prior biologic use,b n (%) 
anti-TNF-α 
anti-IL-17A 
11 (19.3) 
  5 (  8.8) 
  8 (14.0) 
  51 (30.0) 
    8 (  4.7) 
  39 (22.9) 
  44 (26.7) 
    4 (  2.4) 
  38 (23.0) 
  48 (28.7) 
    4 (  2.4) 
  35 (21.0) 
anti-IL-12/23   1 (  1.8)     9 (  5.3)     5 (  3.0)   16 (  9.6) 
aPresence of concurrent psoriatic arthritis was self-reported with medical history 450 
bPatients may have had exposure to >1 prior biologic therapy but ≤2 per exclusion criteria 451 
BMI, body mass index; BSA, body surface area; CZP, certolizumab pegol; DLQI, Dermatology Life 452 
Quality Index; ETN, etanercept; IL, interleukin; PASI, psoriasis area and severity index; 453 
PGA, physician’s global assessment; Q2W, every 2 weeks; TNF, tumor necrosis factor  454 
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Table 2. Primary and Secondary Efficacy Endpoints to Weeks 12 and 16a 455 
 
Placebo 
(N=57) 
CZP 200 mg Q2W 
(N=165) 
CZP 400 mg Q2W 
(N=167) 
Primary Endpoint vs Placebo    
Week 12 
PASI 75 responder rate, % 5.0 61.3 66.7 
OR vs placebo (95% CI) 
p-value  
30.0 (9.0, 100.5) 
<0.0001 
38.0 (11.3, 127.6) 
<0.0001 
Secondary Endpoints vs Placebo    
Week 12 
PGA 0/1 responder rate, % 1.9 39.8 50.3 
OR (95% CI) 
p-value  
36.6 (5.1, 264.2) 
0.0004 
56.1 (7.8, 404.6) 
<0.0001 
PASI 90 responder rate, % 0.2 31.2 34.0 
OR (95% CI) 
p-value  
35.1 (7.4, 167.2) 
<0.0001 
39.9 (8.4, 189.8) 
<0.0001 
Week 16 
PASI 75 responder rate, % 3.8 68.2 74.7 
OR (95% CI) 
p-value  
55.4 (13.1, 233.8) 
<0.0001 
76.3 (18.0, 324.1) 
<0.0001 
PGA 0/1 responder rate, % 3.4 48.3 58.4 
OR (95% CI) 
p-value  
27.2 (6.5, 113.5) 
<0.0001 
40.7 (9.7, 170.2) 
<0.0001 
PASI 90 responder rate, % 0.3 39.8 49.1 
OR (95% CI) 
p-value  
49.5 (10.0, 245.3) 
<0.0001 
72.3 (14.7, 356.6) 
<0.0001 
Secondary Endpoint vs ETN 
ETN 
(N=170) 
CZP 200 mg Q2W 
(N=165) 
CZP 400 mg Q2W 
(N=167) 
Week 12 
PASI 75 responder rate, % 53.3 61.3 66.7 
Difference in responder 
rate, estimate (95% CI)  8.0 (-2.9, 18.9) 13.4 (2.7, 24.1) 
OR (95% CI) 
p-value 
 1.4 (0.9, 2.2) 
0.1523 
1.8 (1.1, 2.8) 
0.0152 
aResponder rates based on logistic regression model 456 
CI, confidence interval; CZP, certolizumab pegol; ETN, etanercept; OR, odds ratio; PASI 75, ≥75% 457 
reduction from Baseline in psoriasis area and severity index; PASI 90, ≥90% reduction from Baseline in 458 
psoriasis area and severity index; PGA 0/1, ‘clear’ or ‘almost clear’ with ≥2‐category improvement from 459 
Baseline in physician’s global assessment; Q2W, every 2 weeks  460 
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Table 3. Summary of Treatment-Emergent Adverse Events From Baseline to Week 12 (Safety Set) 461 
  Placebo 
(N=57) 
ETN 
(N=168) 
CZP 
200 mg Q2W 
(N=165) 
CZP 
400 mg Q2W 
(N=167) 
TEAEs, n (%) [incidence ratea]     
Any 
Drug-relatedb 
Serious 
  32 (56.1) [393.3] 
  7 (12.3) 
  5 (  8.8) [41.0] 
  78 (46.4) [295.6] 
20 (11.9) 
  1 (  0.6) [  2.7] 
  78 (47.3) [299.5] 
16 (9.7) 
  1 (  0.6) [  2.7] 
  82 (49.1) [309.2] 
22 (13.2) 
  4 (  2.4) [10.6] 
Discontinuations due to TEAE, n (%) 0 4 (2.4) 1 (0.6) 1 (0.6) 
Deaths, n (%) 0 0 0 0 
Most frequently reported TEAEs,c 
n (%) [incidence rate]a 
    
Nasopharyngitis 
Upper respiratory tract infection 
  5 (  8.8) [40.8] 
  6 (10.5) [47.7] 
11 (  6.5) [31.0] 
11 (  6.5) [30.2] 
14 (  8.5) [38.8] 
  6 (  3.6) [16.2] 
12 (  7.2) [32.9] 
  8 (  4.8) [21.5] 
Other TEAEs of interest, n (%) 
[incidence ratea] 
    
Infections and infestations 16 (28.1) [140.7]   39 (23.2) [120.0]   44 (26.7) [134.9]   38 (22.8) [113.1] 
Latent tuberculosis 0    1 (  0.6) [  2.7] 0 0 
Candida infections 0     1 (  0.6) [  2.7]d 0 0 
Oral fungal infection  0 0 0 0 
Fungal skin infection 0 0 0    1 (  0.6) [  2.6]e 
Herpes zoster   1 (  1.8) [  7.8] 0 0 0 
Serious infections and infestations 0 0 0    1 (  0.6) [  2.6]f 
Malignancy 0 0 0 0 
Depression 0 0   1 (  0.6) [  2.7] 0 
aIncidence of new cases per 100 patient-years 462 
bIncidence rate not calculated 463 
c
≥5% in any CZP group 464 
dSkin Candida 465 
eReported as fungal infection preferred term in the database 466 
fPneumonia 467 
Total exposure for all CZP patients from Baseline to Week 12 = 75.72 patient-years 468 
CZP, certolizumab pegol; ETN, etanercept; Q2W, every 2 weeks; TEAE, treatment-emergent adverse 469 
event 470 
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SUPPLEMENT 1 
 2 
METHODS 3 
To account for multiplicity, a fixed-sequence testing procedure was used: superiority to placebo for 4 
PASI 75, PGA 0/1, and then PASI 90 using a 2-sided alpha level of 0.05 was evaluated at Week 12 and 5 
then at Week 16. At each step, CZP 400 mg Q2W was assessed first, followed by CZP 200 mg Q2W. 6 
Following these comparisons with placebo, CZP 400 mg Q2W was assessed for noninferiority to ETN at 7 
Week 12 based on a prespecified 10% noninferiority margin. Subsequently, CZP 400 mg Q2W was 8 
assessed for superiority to ETN at Week 12, and CZP 200 mg Q2W was assessed for noninferiority to 9 
ETN at Week 12 based on prespecified 10% noninferiority margin. These two assessments were 10 
performed simultaneously where multiplicity was controlled based on the Hochberg method. Finally, 11 
CZP 200 mg Q2W was assessed for superiority to ETN at Week 12. This procedure controlled the overall 12 
Type 1 error rate at 5%. 13 
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SUPPLEMENTAL TABLES 1 
 2 
Table S1. Summary of Treatment-Emergent Adverse Events From Baseline to Week 48 (Safety Set) 3 
  CZP 200 mg Q2Wa,b  
(N=265) 
CZP 400 mg Q2Wa 
(N=354) 
TEAEs, n (%) [incidence ratec] 
Any  
Drug-relatedd 
Serious  
 
175 (66.0) [214.0] 
40 (15.1) 
12 (4.5) [7.7] 
 
  230 (65.0) [201.3] 
58 (16.4) 
  23 (  6.5) [11.3] 
Discontinuations due to TEAE, n (%) 4 (1.5) 11 (3.1) 
Deaths, n (%) 0 0 
Most frequently reported TEAEs,e n (%) [incidence ratec]   
Nasopharyngitis 
Upper respiratory tract infection 
Hypertension 
Viral upper respiratory tract infection 
35 (13.2) [23.6] 
16 (  6.0) [10.5] 
10 (  3.8) [  6.5] 
14 (  5.3) [  9.1] 
  44 (12.4) [22.6] 
  29 (  8.2) [14.4] 
  17 (  4.8) [  8.3]     
    8 (  2.3) [  3.8] 
Other TEAEs of interest, n (%) [incidence ratec]   
Infections and infestations 108 (40.8) [93.8] 132 (37.3) [79.7] 
Tuberculosis 0     1 (  0.3) [  0.5] 
Candida infections 0      2 (  0.6) [  1.0]f 
Oral fungal infection  0 0 
Fungal skin infection 0      1 (  0.3) [  0.5]g 
Herpes zoster     3 (  1.1) [  1.9]     2 (  0.6) [  1.0] 
Serious infections and infestations      3 (  1.1) [  1.9]h      6 (  1.7) [  2.9]i 
Malignancy 0     2 (  0.6) [  1.0] 
Multiple sclerosis 0      1 (  0.3) [  0.5]j 
Microscopic colitis 0     1 (  0.3) [  0.5] 
Depression     4 (  1.5) [  2.5]     1 (  0.3) [  0.5] 
aPatients who switched doses could have been counted in both CZP doses 4 
bPatients receiving CZP 400 mg Q4W were included in the CZP 200 mg Q2W group (same cumulative 5 
monthly dose) 6 
cIncidence of new cases per 100 patient-years 7 
dIncidence rate not calculated 8 
e
≥5% in any group 9 
fCandida infection, oral candidiasis, skin Candida, and vulvovaginal candidiasis in the same patient; 10 
genital candidiasis in a different patient   11 
gReported as fungal infection preferred term in the database 12 
hGastroenteritis, pancreas infection, and pneumonia 13 
iEscherichia coli sepsis and pyelonephritis in the same patient; endophthalmitis, pneumonia, sepsis, 14 
erysipelas, and tuberculosis each in one patient 15 
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jPrimary progressive multiple sclerosis; incidental finding during evaluation for low back pain (no TEAEs 16 
during study) and considered unrelated to treatment by the Investigator 17 
Total exposure for all CZP patients from Baseline to Week 48 = 370.81 patient-years 18 
CZP, certolizumab pegol; Q2W, every 2 weeks; Q4W, every 4 weeks; TEAE, treatment-emergent 19 
adverse event 20 
  21 
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Table S2. Summary of Serious TEAEs to Week 48  22 
 Placebo 
(N=57) 
ETN 
(N=168) 
CZP 200 mg Q2W 
(N=165) 
CZP 400 mg Q2W 
(N=167) 
Any serious TEAE, 
n (%) [incidencea] 6 (  10.5) [37.5] 1 (  0.6) [  2.7]   1 (  0.6) [  2.0]   7 (  4.2) [14.0] 
Baseline to 
Week 16b 
Inguinal hernia 
Hepatic enzyme 
increased 
Back pain 
Metrorrhagia 
Rectocele 
Ulna fracture 
 
Hepatic enzyme 
increased 
Polymyalgia rheumatica Pneumonia 
Lower limb fracture 
Migraine 
Bipolar I disorder 
Osteoarthritis 
Abdominal pain 
Acute coronary syndrome 
 
   CZP 200 mg Q2W 
(N=144) 
CZP 400 mg Q4W 
(N=44) 
CZP 400 mg Q2Wc 
(N=273) 
Any serious TEAE, 
n (%) [incidencea] 
 
 7 (  4.9) [  8.6] 4 (  9.1) [16.0] 16 (  5.9) [10.3] 
Week 16 to 
Week 48 
  Peptic ulcer 
Hepatitis 
Gastroenteritis 
Foot fracture, facial 
bones fracture, rib 
fracture 
Osteoarthritis 
Pregnancy with 
contraceptive 
device 
Uterine cyst 
 
Pancreas infection 
Pneumonia 
Forearm fracture 
Psoriatic 
arthropathy 
 
Cardiac failure  
Cataract 
Hemorrhoids 
Cholecystitis 
Escherichia coli sepsis, 
pyelonephritis 
Endophthalmitis 
Sepsis 
Erysipelas 
Tuberculosis 
Ulna fracture 
Wrist fracture, rib fracture, 
laceration, compartment syndrome 
Anaplastic oligodendroglioma, 
concussion 
Migraine 
Primary progressive MSd 
Nephrolithiasis 
Guttate psoriasis 
 
aIncidence of new cases per 100 patient-years 23 
bData to Week 12 are presented for ETN 24 
cIncludes patients who entered the Escape Arm for treatment with CZP 400 mg Q2W  25 
dPrimary progressive multiple sclerosis; incidental finding during evaluation for low back pain (no 26 
TEAEs during study) and considered unrelated to treatment by the Investigator  27 
Each box represents a single patient 28 
CZP, certolizumab pegol; ETN, etanercept; MS, multiple sclerosis; Q2W, every 2 weeks; Q4W, every 4 29 
weeks; TEAE, treatment-emergent adverse event 30 
